PD32-12 CERAMIDE TEST IN PATIENTS WITH ERECTILE DISFUNCTION TO ASSESS CARDIOVASCULAR RISK

Le résumé fourni par la source

You have accessJournal of UrologySexual Function/Dysfunction: Evaluation II (PD32)1 May 2024PD32-12 CERAMIDE TEST IN PATIENTS WITH ERECTILE DISFUNCTION TO ASSESS CARDIOVASCULAR RISK Andres Guillen Lozoya, Mihai Dumbrava, Jayson Kemble, Abrar Mian, Sevann Helo, Matthew Ziegelmann, Scott Collins, and Tobias Kohler Andres Guillen LozoyaAndres Guillen Lozoya , Mihai DumbravaMihai Dumbrava , Jayson KembleJayson Kemble , Abrar MianAbrar Mian , Sevann HeloSevann Helo , Matthew ZiegelmannMatthew Ziegelmann , Scott CollinsScott Collins , and Tobias KohlerTobias Kohler View All Author Informationhttps://doi.org/10.1097/01.JU.0001009364.27111.54.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Erectile dysfunction (ED) is a known precursor and sequelae to diagnosed cardiovascular disease (CVD). ED severity predicts CVD severity. AUA guidelines recommend evaluating serum lipids and using an ED diagnosis as an opportunity to discuss and address cardiovascular risk. Serum plasma ceramides are novel predictors of adverse cardiovascular events independent of traditional risk factors such as LDL and hsCRP levels, ceramide scores greater than 6 points have been associated with a 2.5 fold increase in the risk to develop cardiovascular death within 5 years. Ceramide levels improve with lifestyle modification. The aim of this study is to evaluate the utility of ceramide levels in ED patients utilizing self-reported erectile function results (IIEF-6). METHODS: We initiated ceramide testing in all patients with ED and Peyronie's disease in late 2019 (in addition to lipids and Hgba1c). We retrospectively analyzed ceramide levels from electronic records with IIEF-6 results. For the statistical analysis we dichotomized our cohort by ED symptom severity (moderate/severe ED: IIEF≤17 vs. no/mild ED: IIEF≥18) and ceramide levels by CV risk strata (moderate or higher>6). A Fisher exact test was performed. RESULTS: A total of 365 patients were reviewed, of these 238 (65.2%) had mild to moderate ED symptom level or higher. A statistically significant difference in abnormal ceramide values was found in patients with mild to moderate symptoms severity or higher, and the odds of getting an abnormal ceramide test was increased based on the IIEF scoring alone (OR 2.1 [1.05 – 4.31]; p value=0.033). CONCLUSIONS: Patients undergoing management for erectile dysfunction may benefit from serum ceramide testing and subsequent cardiac referral. In our cohort, men with moderate to severe ED were twice as likely to have actionable ceramide levels. Further study is warranted to optimize utility of ceramide in men with ED and potentially drive lifestyle change. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e708 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Andres Guillen Lozoya More articles by this author Mihai Dumbrava More articles by this author Jayson Kemble More articles by this author Abrar Mian More articles by this author Sevann Helo More articles by this author Matthew Ziegelmann More articles by this author Scott Collins More articles by this author Tobias Kohler More articles by this author Expand All Advertisement PDF downloadLoading ...

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.